Clinical Trial Update: An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack [Phase 3]

View source ↗

Summary

Phase 3 efficacy study of PRO-513 for migraine completed; results are not provided in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• PRO-513

Snippet

Sponsor: ProEthic Pharmaceuticals | Conditions: Migraine, Photophobia | Phase 3 | Status: COMPLETED